Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis

Authors Piet Geusens, Willem Lems

Published 11 April 2008 Volume 2008:4(2) Pages 337—344


Piet Geusens1, Willem Lems2

1Department of Internal Medicine, Subdivision of Rheumatology, University Hospital, Maastricht, The Netherlands and Biomedical Research Institute, University Hasselt, Belgium; 2Vrije Universiteit Medical Centre, Department of Rheumatology, Amsterdam, the Netherlands

Abstract: Lumiracoxib is a COX2 inhibitor that is highly selective, is more effective than placebo on pain in osteoarthritis (OA), with similar analgesic and anti-inflammatory effects as non-selective NSAIDs and the selective COX2 inhibitor celecoxib, has a lower incidence of upper gastrointestinal (GI) side effects in patients not taking aspirin, and a similar incidence of cardiovascular (CV) side effects compared to naproxen or ibuprofen. In the context of earlier guidelines and taking into account the GI and CV safety results of the TARGET study, lumiracoxib had secured European Medicines Agency (EMEA) approval with as indication symptomatic treatment of OA as well as short-term management of acute pain associated with primary dysmenorrhea and following orthopedic or dental surgery. In the complex clinical context of efficiency and safety of selective and non-selective COX inhibitors, its prescription and use should be based on the risk and safety profile of the patient. In addition, there is further need for long-term GI and CV safety studies and general post-marketing safety on its use in daily practice. Meanwhile, at the time of submission of this manuscript, the EMEA has withdrawn lumiracoxib throughout Europe because of the risk of serious side effects affecting the liver.

Keywords: lumiracoxib, NSAIDs, COX2 inhibitors, gastro-intestinal and cardiovascular safety

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Resolution of vitreomacular traction following intravitreal ranibizumab in cases of ocular toxoplasmosis with choroidal neovascularization

Petrou P, Georgalas I, Markomichelakis N, Vergados I, Gianakaki E, Rouvas A

Therapeutics and Clinical Risk Management 2013, 9:391-394

Published Date: 18 October 2013

Teenage outcomes after speech and language impairment at preschool age

Ek U, Norrelgen F, Westerlund J, Dahlman A, Hultby E, Fernell E

Neuropsychiatric Disease and Treatment 2012, 8:221-227

Published Date: 15 May 2012

Update on pediatric dystonias: etiology, epidemiology, and management

Fernández-Alvarez E, Nardocci N

Degenerative Neurological and Neuromuscular Disease 2012, 2:29-41

Published Date: 12 April 2012

Tapentadol in the management of chronic low back pain: a novel approach to a complex condition?

Pergolizzi J, Alon E, Baron R, Bonezzi C, Dobrogowski J, Gálvez R, Jensen T, Kress H-G, Marcus MA, Morlion B, Perrot S, Treede R-D

Journal of Pain Research 2011, 4:203-210

Published Date: 21 July 2011

Intracellular heavy metal nanoparticle storage: progressive accumulation within lymph nodes with transformation from chronic inflammation to malignancy

Tommaso Iannitti, Stefania Capone, Antonietta Gatti, et al

International Journal of Nanomedicine 2010, 5:955-960

Published Date: 15 November 2010

RhoA/Rho-kinase signaling: a therapeutic target in pulmonary hypertension

Scott A Barman, Shu Zhu, Richard E White

Vascular Health and Risk Management 2009, 5:663-671

Published Date: 9 August 2009

Treatment of pediatric pulmonary hypertension

Amy Hawkins, Robert Tulloh

Vascular Health and Risk Management 2009, 5:509-524

Published Date: 3 June 2009

New advances in the treatment of Clostridium difficile infection (CDI)

Dennis D Hedge, Joe D Strain, Jodi R Heins, Debra K Farver

Therapeutics and Clinical Risk Management 2008, 4:949-964

Published Date: 10 October 2008

Review of the combined contraceptive vaginal ring, NuvaRing®

Frans JME Roumen

Therapeutics and Clinical Risk Management 2008, 4:441-451

Published Date: 11 April 2008

Treatment of non-alcoholic fatty liver disease

Keith G Tolman, Anthony S Dalpiaz

Therapeutics and Clinical Risk Management 2007, 3:1153-1163

Published Date: 15 January 2008